ProPhase Labs, Inc. (NASDAQ:PRPH – Get Free Report)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.47 and traded as low as $2.48. ProPhase Labs shares last traded at $2.53, with a volume of 14,002 shares traded.
Analyst Ratings Changes
Separately, StockNews.com raised shares of ProPhase Labs to a “sell” rating in a research note on Wednesday, June 26th.
Read Our Latest Stock Analysis on ProPhase Labs
ProPhase Labs Price Performance
Hedge Funds Weigh In On ProPhase Labs
An institutional investor recently raised its position in ProPhase Labs stock. Vanguard Group Inc. increased its stake in ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report) by 1.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 618,763 shares of the company’s stock after buying an additional 9,416 shares during the period. Vanguard Group Inc. owned 3.43% of ProPhase Labs worth $4,003,000 at the end of the most recent reporting period. Institutional investors own 9.45% of the company’s stock.
About ProPhase Labs
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Featured Articles
- Five stocks we like better than ProPhase Labs
- 3 Stocks to Consider Buying in October
- 3 Small Cap Stocks That Insiders Are Buying
- How to Invest in the Best Canadian Stocks
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.